A Competition That Isn’t Only About the Drug

When new Alzheimer’s treatments reach the market, the focus usually falls on the drug itself—how effectively it removes amyloid plaques, how much it slows cognitive decline, and how safe it is.

But for disease-modifying therapies like Leqembi, the medication is only part of the equation.

These treatments depend on a complex medical pathway that includes:

• Early diagnosis
• Biomarker confirmation
• Imaging monitoring
• Infusion-based treatment

This means the drug that fits best into the existing healthcare infrastructure may gain an important advantage.

Why Alzheimer’s Treatment Now Requires Biological Diagnosis

For decades, Alzheimer’s disease was diagnosed mainly through symptoms and cognitive testing.

That has changed.

Modern anti-amyloid therapies are prescribed only when doctors confirm that amyloid plaques are actually present in the brain. This confirmation usually requires one of several tests:

• Amyloid PET brain imaging
• Cerebrospinal fluid analysis
• Emerging blood biomarker tests

Without this confirmation, physicians generally will not start treatment because the drug specifically targets amyloid pathology.

This shift has transformed Alzheimer’s care from a symptom-based diagnosis into a biologically confirmed disease model.

The Infrastructure Leqembi Helped Create

When U.S. Food and Drug Administration granted full approval to Leqembi in 2023, health systems around the world had to quickly prepare for an entirely new type of Alzheimer’s treatment.

Hospitals and clinics began building the systems required to support it.

That included:

• Expanding amyloid PET scanning programs
• Establishing infusion clinics for treatment
• Creating MRI monitoring protocols to detect ARIA
• Training neurologists in biomarker-based diagnosis

In effect, Leqembi’s rollout triggered the creation of a new Alzheimer’s treatment ecosystem.

And once healthcare systems invest in that infrastructure, they tend to continue using it.

Why Infrastructure Often Determines Which Treatment Wins

In real clinical practice, adoption of a therapy often depends on how easily it fits into existing workflows.

If a medical center already has:

• referral systems for amyloid testing
• MRI safety monitoring protocols
• infusion centers designed for anti-amyloid drugs
• neurologists trained in biomarker diagnosis

then prescribing Leqembi becomes straightforward.

Switching to a different therapy may require new workflows, additional training, or different monitoring routines.

Healthcare systems typically prefer the pathway they already know how to operate.

Why this matters for families

A treatment is only as accessible as the system behind it. If a center already has referral habits, amyloid testing access, MRI monitoring routines, and infusion workflows in place, that center is more likely to use the therapy it already knows how to deliver smoothly. That is where Leqembi may hold a meaningful real-world advantage today.

The Diagnostic Pipeline Is Rapidly Expanding

Another factor that could strengthen Leqembi’s position is the rapid development of Alzheimer’s blood tests.

Several research groups are developing blood-based biomarkers capable of detecting amyloid or tau proteins associated with Alzheimer’s disease.

These tests may soon allow physicians to:

• Screen patients in primary care clinics
• Identify likely Alzheimer’s cases earlier
• Refer confirmed patients for treatment faster

If these tests become widely available, the number of people diagnosed in the early stages of Alzheimer’s disease could grow significantly.

Because Leqembi already helped establish treatment pathways, it may be well positioned to benefit from this expanding diagnostic pipeline.

What About Competing Therapies?

New therapies are entering the market, including Kisunla.

These treatments also require amyloid confirmation and MRI safety monitoring. But Leqembi’s earlier rollout has given many healthcare systems time to develop protocols and experience with the treatment process.

In healthcare, the first therapy to establish a practical treatment model often retains a lasting advantage.

What This Means for Families and Caregivers

For families facing memory concerns, the most important takeaway may be this:

Early diagnosis is becoming increasingly important.

Disease-modifying therapies appear to work best in the earliest stages of Alzheimer’s disease. The expanding diagnostic infrastructure—imaging centers, biomarker tests, and specialized clinics—makes early detection more possible than it was only a few years ago.

Families who pursue evaluation early may gain access to:

• more treatment options
• more time to plan care decisions
• clearer understanding of the disease

The Bigger Shift in Alzheimer’s Care

The arrival of drugs like Leqembi may mark the beginning of a broader transformation in Alzheimer’s medicine.

Instead of diagnosing the disease only after major cognitive decline appears, physicians are increasingly aiming to:

• detect Alzheimer’s earlier
• confirm it biologically
• begin treatment sooner

This approach mirrors how other major diseases—such as cancer and heart disease—are treated today.

Takeaway

The future of Alzheimer’s therapy may not depend solely on which drug performs best in clinical trials.

It may also depend on which therapy already has the diagnostic and treatment ecosystem built around it.

By forcing healthcare systems to develop biomarker testing, imaging protocols, and infusion pathways, Leqembi has helped create a medical infrastructure that competitors will now have to enter rather than build from scratch.

That hidden advantage could play an important role in how Alzheimer’s treatments are used in the real world.